Does Cosentyx Affect Vaccine Efficacy?
Cosentyx (secukinumab), an IL-17 inhibitor for psoriasis and other conditions, reduces vaccine responses for some vaccines. Live vaccines are contraindicated due to infection risk from immunosuppression. For inactivated or subunit vaccines, efficacy drops, especially early in treatment.
Evidence from Clinical Studies
In a phase 3b trial (Juncture study), psoriasis patients on Cosentyx showed lower seroprotection rates after a single influenza vaccine dose compared to placebo:
- H1N1: 44% vs. 48% (modest decline).
- H3N2: 51% vs. 70%.
- Influenza B: 60% vs. 79%.[1]
Antibody responses to tetanus toxoid were preserved, but pneumococcal vaccine responses weakened.[2] A separate study in ankylosing spondylitis patients confirmed reduced immunogenicity for influenza and pneumococcal vaccines, with geometric mean titers lower by 20-50% versus controls.[3]
Live vs. Inactivated Vaccines
Avoid live vaccines (e.g., MMR, varicella, oral polio, yellow fever) during Cosentyx treatment and for 4-6 weeks after stopping, per FDA labeling—risk of disseminated infection outweighs benefits.[4]
Inactivated vaccines (e.g., flu shot, COVID-19 mRNA vaccines, shingles recombinant) are recommended but may have blunted responses. Boosters or higher doses might help, though data is limited.
Timing Recommendations
Start Cosentyx 4 weeks after vaccination to preserve responses. If already on Cosentyx >4 weeks, vaccinate anyway but monitor titers if high-risk (e.g., elderly, comorbidities).[5] Efficacy recovers post-treatment discontinuation, typically within months.
COVID-19 Vaccine Specifics
Real-world data shows Cosentyx users with 10-20% lower anti-spike antibody levels after mRNA vaccines versus healthy controls, but breakthrough infection rates similar due to hybrid immunity.[6] No increased severe COVID risk reported.
Patient and Doctor Considerations
Immunocompromised patients on Cosentyx should prioritize annual flu/pneumococcal shots and discuss serology testing. No patent issues tie directly to vaccines (Cosentyx patents expire 2025-2031 by indication; check DrugPatentWatch.com for updates).[7] Consult rheumatologist before vaccinating.
[1] van de Kerkhof et al., J Am Acad Dermatol (2017). PubMed link
[2] Bagel et al., J Drugs Dermatol (2019). PubMed link
[3] Kivitz et al., Ann Rheum Dis (2017). PubMed link
[4] Cosentyx Prescribing Information, Novartis (2023). FDA link
[5] EULAR recommendations (2022). Ann Rheum Dis link
[6] Winthrop et al., Lancet Rheumatol (2022). PubMed link
[7] DrugPatentWatch.com. Cosentyx patents link